Replies to post #127900 on Biotech Values

[DewDiligence]

I have my fingers crossed that PKI doesn’t issue a similar sounding PR in the next two weeks. There is so much pessimism based into PKI’s share price that the stock should do pretty well if they merely report an in-line third quarter.

[dav1234]

wow ILMN lost $10 on that, trying a small trade @ 30.50, thinking the drop is a bit overdone

[hptaxis]

ILMN LINK: http://investor.illumina.com/phoenix.zhtml?c=121127&p=irol-newsArticle&ID=1614675&highlight=

I have had them on an occasional watch list, but this makes me seriously think about buying. Have you seen the 23andme offer of a $999 genome? https://www.23andme.com/exome/

The Future Is Now: 23andMe Now Offers All Your Genes For $999 - http://www.forbes.com/sites/matthewherper/2011/09/27/the-future-is-now-23andme-now-offers-all-your-genes-for-999/

Who does their sequencing?

[DewDiligence]

At the current share price, PKI has a trailing P/E of about 6. The market for biotech tools and instruments may be weak, but I don’t think it’s as weak as implied by today’s price action. Moreover, a big chunk of PKI’s revenue comes from annuity-like service contracts.